[go: up one dir, main page]

ES510042A0 - "un procedimiento de preparacion de nuevas carboxamidas heterociclicas". - Google Patents

"un procedimiento de preparacion de nuevas carboxamidas heterociclicas".

Info

Publication number
ES510042A0
ES510042A0 ES510042A ES510042A ES510042A0 ES 510042 A0 ES510042 A0 ES 510042A0 ES 510042 A ES510042 A ES 510042A ES 510042 A ES510042 A ES 510042A ES 510042 A0 ES510042 A0 ES 510042A0
Authority
ES
Spain
Prior art keywords
preparation
carboxamides
procedure
heterociclic
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES510042A
Other languages
English (en)
Other versions
ES8400409A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo AB
Original Assignee
Leo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo AB filed Critical Leo AB
Publication of ES8400409A1 publication Critical patent/ES8400409A1/es
Publication of ES510042A0 publication Critical patent/ES510042A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
ES510042A 1981-03-03 1982-03-02 "un procedimiento de preparacion de nuevas carboxamidas heterociclicas". Granted ES510042A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8106594 1981-03-03

Publications (2)

Publication Number Publication Date
ES8400409A1 ES8400409A1 (es) 1983-10-16
ES510042A0 true ES510042A0 (es) 1983-10-16

Family

ID=10520089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES510042A Granted ES510042A0 (es) 1981-03-03 1982-03-02 "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".

Country Status (21)

Country Link
US (2) US4547511A (es)
EP (1) EP0059698B1 (es)
JP (1) JPS57171975A (es)
KR (1) KR860001876B1 (es)
AT (1) ATE15798T1 (es)
AU (1) AU547849B2 (es)
CA (1) CA1182455A (es)
DE (1) DE3266464D1 (es)
DK (1) DK157859C (es)
ES (1) ES510042A0 (es)
FI (1) FI79532C (es)
GR (1) GR76073B (es)
HK (1) HK38689A (es)
HU (1) HU186909B (es)
IE (1) IE52670B1 (es)
IL (1) IL65028A (es)
NO (1) NO163130C (es)
NZ (1) NZ199888A (es)
PH (1) PH18520A (es)
PT (1) PT74512B (es)
ZA (1) ZA821210B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269753A (en) * 1964-08-31 1966-08-30 Data Man Inc Bookkeeping unit
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4400017A (en) * 1981-03-04 1983-08-23 Pendergrass Russell G Integrated budget and check record book
US4650804A (en) * 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE8902076D0 (sv) * 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
US5691350A (en) * 1990-02-22 1997-11-25 Kabi Pharmacia Ab Use of linomide for treatment of retrovirus infections specifically HIV infections
US5504092A (en) * 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use
CA2091171A1 (en) * 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds
WO1992004327A1 (en) * 1990-09-07 1992-03-19 Schering Corporation Antiviral compounds and antihypertensive compounds
EP0550464A1 (en) * 1990-09-07 1993-07-14 Schering Corporation Antiviral compounds and antihypertensive compounds
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
TW222276B (es) * 1992-01-27 1994-04-11 Fujisawa Pharmaceutical Co
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
GB9311562D0 (en) * 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
CN1215835C (zh) * 1996-03-27 2005-08-24 东丽株式会社 酮衍生物及其在医学上的应用
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
JP2000044561A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ピロロキノリン誘導体及びその製造方法
JP2000044560A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ベンゾキノリジン誘導体及びその製造方法
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
RU2240313C2 (ru) * 1999-10-25 2004-11-20 Эктив Байотек Аб Лекарственные средства для лечения злокачественных опухолей
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
WO2001034570A1 (en) * 1999-11-08 2001-05-17 Sankyo Company, Limited Nitrogenous heterocycle derivatives
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
JP2003012667A (ja) * 2001-06-26 2003-01-15 Rrf Kenkyusho:Kk キノリンカルボキサミド骨格を有する抗菌剤
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
WO2004104000A1 (ja) * 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
US7228698B2 (en) * 2005-06-30 2007-06-12 Premark Feg L.L.C. Refrigeration unit
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2009133468A1 (en) * 2008-04-28 2009-11-05 Actavis Group Ptc Ehf Improved process for preparing quinoline-3-carboxamide derivatives
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
TWI465449B (zh) 2008-10-23 2014-12-21 Vertex Pharma 囊腫性纖維化跨膜傳導調節因子之調控因子
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US20120009226A1 (en) * 2008-12-17 2012-01-12 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
PL2467372T3 (pl) * 2009-08-10 2017-04-28 Teva Pharmaceutical Industries Ltd. Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
US8889661B2 (en) * 2010-03-03 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of lupus nephritis using laquinimod
KR20130014523A (ko) * 2010-03-03 2013-02-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료
PH12012501741A1 (en) * 2010-03-03 2012-11-12 Teva Pharma Treatment of lupus arthritis using laquinimod
KR20130041193A (ko) * 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
SG186948A1 (en) 2010-07-09 2013-02-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EA201491517A1 (ru) 2012-02-16 2015-03-31 Тева Фармасьютикал Индастриз Лтд. N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
CN104955522A (zh) 2012-11-07 2015-09-30 梯瓦制药工业有限公司 拉喹莫德胺盐
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CA3179303A1 (en) * 2020-05-21 2021-11-25 Darren Orton Notch inhibitors and uses thereof
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
WO2024097606A1 (en) 2022-10-31 2024-05-10 Eli Lilly And Company Ahr agonists
WO2024107555A1 (en) * 2022-11-15 2024-05-23 Eli Lilly And Company Ahr agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471784A (de) * 1966-01-26 1969-04-30 Bayer Ag Verfahren zur Herstellung von Carbostyrilderivaten
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
CH578537A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578535A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578536A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578534A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
US3917609A (en) * 1973-06-27 1975-11-04 Minnesota Mining & Mfg Pyrroloquinoline carboxylic acids and derivatives
FR2281761A1 (fr) * 1974-08-13 1976-03-12 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation

Also Published As

Publication number Publication date
US4738971A (en) 1988-04-19
IL65028A (en) 1986-11-30
NO163130C (no) 1990-04-11
ATE15798T1 (de) 1985-10-15
KR830009037A (ko) 1983-12-17
ZA821210B (en) 1983-01-26
IL65028A0 (en) 1982-04-30
PT74512B (en) 1983-11-08
EP0059698A1 (en) 1982-09-08
AU547849B2 (en) 1985-11-07
IE52670B1 (en) 1988-01-20
ES8400409A1 (es) 1983-10-16
CA1182455A (en) 1985-02-12
HU186909B (en) 1985-10-28
DK157859C (da) 1990-07-30
US4547511A (en) 1985-10-15
FI79532B (fi) 1989-09-29
NZ199888A (en) 1985-07-31
KR860001876B1 (ko) 1986-10-24
JPH049786B2 (es) 1992-02-21
NO820642L (no) 1982-09-06
JPS57171975A (en) 1982-10-22
NO163130B (no) 1990-01-02
GR76073B (es) 1984-08-03
DE3266464D1 (en) 1985-10-31
EP0059698B1 (en) 1985-09-25
FI820728L (fi) 1982-09-04
PT74512A (en) 1982-04-01
DK81282A (da) 1982-09-04
DK157859B (da) 1990-02-26
AU8107682A (en) 1982-09-09
HK38689A (en) 1989-05-19
IE820314L (en) 1982-09-03
FI79532C (fi) 1990-01-10
PH18520A (en) 1985-08-02

Similar Documents

Publication Publication Date Title
ES510042A0 (es) "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".
OA06914A (fr) Procédé de préparation d'iminodiacides substitués.
FR2417500A1 (fr) Derives d'amino-acides cycliques dehydrogenes et leur utilisation therapeutique
FR2430411A1 (fr) Phenethanolamines et leur utilisation therapeutique
SE8300912D0 (sv) Kompositioner for behandling av glaukom
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
IT1194748B (it) Composizioni farmaceutiche per il trattamento di osteopatie
ES513138A0 (es) "procedimiento de preparacion de compuestos del tipo arilbencensulfonamida".
DE3261760D1 (en) Pharmaceutical compositions for the treatment of skin
RO83114A (ro) Procedeu pentru prepararea ditiazolil-(2,2')-disulfurilor
SE8300913D0 (sv) Kompositioner for behandling av glaukom
DE3268024D1 (en) 0-alkyl-0-carbamoyl-glycero-phospho-cholines and process for their preparation
FR2417499A1 (fr) Mercaptoacylamino-acides halogenes et leur utilisation therapeutique
GB2105992B (en) Pharmaceutical composition for treatment of cardio-vascular diseases
BE894228A (fr) Composition pharmaceutique pour le traitement de l'atherosclerose
NO158299C (no) Analogifremgangsmaate for fremstilling av 17, 18-dehydro-apovincaminol-l-3', 4', 5'-trimethoxy-benzoat.
NO147232C (no) Fremgangsmaate for aa forbedre den biologiske taalbarhet av polyamidimplanteringsproteser
BE892339A (fr) Agents pour le traitement d'affections cardiaques coronariennes
RO81791A2 (ro) Comprimate pentru tratamentul uremiilor feriprive
RO76072A2 (ro) Compozitie medicamentoasa pentru tratamentul afectiunilor cailor respiratorii superioare
IT1135094B (it) Procedimento per la preparazione dell'l-5-idrossitriptofano
NO147752C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 11(eq)-(2-acyletyl)-2,6-metano-3-benzazociner
NO830614L (no) Fremgangsmaate for behandling av glaukom.
RO82224A2 (ro) Procedeu pentru prepararea pivaloil-beta-alanil-p-aminobenzoatului deetil
RO80161A2 (ro) Procedeu pentru prepararea 5-amino-1h-imidazol-4-carboxamidei